Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2023 | Unmet needs in AML: TP53 mutations and maintenance therapy

Alex Bataller • 11 Dec 2023
ASH 2023
Acute Myeloid Leukemia Leukemia

Alex Bataller, MD, PhD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the unmet needs in acute myeloid leukemia (AML), including treating patients with TP53 mutations and developing effective maintenance therapies to prevent relapse after transplant. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Explore the AML Channel banner with headshots of Naval Daver, Eunice Wang, and Thomas Cluzeau

More from Alex Bataller

The future of precision medicine in MDS: genomic profiling and venetoclax-based strategies
1:55
The future of precision medicine in MDS: genomic profiling and venetoclax-based strategies
Alex Bataller • 8 Jun 2026
Whole genome sequencing reveals clinically relevant alterations missed by standard testing in MDS
1:17
Whole genome sequencing reveals clinically relevant alterations missed by standard testing in MDS
Alex Bataller • 8 Jun 2026
HMA with or without venetoclax in treatment-naïve MDS with excess blasts: a retrospective analysis
1:13
HMA with or without venetoclax in treatment-naïve MDS with excess blasts: a retrospective analysis
Alex Bataller • 8 Jun 2026
Factors influencing the choice of intensive therapy in AML: age, performance status & genetics
1:02
Factors influencing the choice of intensive therapy in AML: age, performance status & genetics
Alex Bataller • 8 Dec 2025

Related Videos

Is there a role for CAR T-cell therapy in the treatment pathway for CLL?
1:21
Is there a role for CAR T-cell therapy in the treatment pathway for CLL?
Marco Ruella • 16 Oct 2026
Access challenges to diagnosis and treatment for patients with CLL in resource-restricted countries
1:45
Access challenges to diagnosis and treatment for patients with CLL in resource-restricted countries
Celso Arrais • 17 Oct 2026
Insights into the current CLL treatment algorithm and emerging research directions
1:51
Insights into the current CLL treatment algorithm and emerging research directions
Matthew Davids • 17 Oct 2026
How has the harmonization of genomic profiling in Sweden impacted patient access to CLL diagnostics?
1:21
How has the harmonization of genomic profiling in Sweden impacted patient access to CLL diagnostics?
Richard Rosenquist • 17 Oct 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals